Chimerix Inc. (CMRX)
3.35
-0.02 (-0.59%)
At close: Jan 15, 2025, 1:34 PM
undefined% (undefined)
| Bid | 3.34 |
| Market Cap | 301.29M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -3.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.36 |
| Volume | 1,156,458 |
| Avg. Volume (20D) | 4,278,131 |
| Open | 3.47 |
| Previous Close | 3.37 |
| Day's Range | 3.25 - 3.47 |
| 52-Week Range | 0.75 - 3.80 |
| Beta | undefined |
About CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midl...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 11, 2013
Employees 72
Stock Exchange NASDAQ
Ticker Symbol CMRX
Website https://www.chimerix.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CMRX stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 153.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Chimerix Inc. is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of $310.60K, reflecting a 7.67K% YoY growth and earnings per share of -0.28, making a 40.00% increase YoY.
Analysts project revenue of $310.60K, reflecting a 7.67K% YoY growth and earnings per share of -0.28, making a 40.00% increase YoY.
1 month ago ·
Source
+219.08%
Chimerix shares are trading higher after the compa...
Unlock content with
Pro Subscription
1 month ago ·
Source
+3.97%
Chimerix shares are trading higher after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.
